TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04264234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Ultrasonography
Description: Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
Study: NCT01755520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg twice daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Ticagrelor
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Aspirin
Description: Placebo
Study: NCT03341650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Pasta
Description: Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Pasta
Description: Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
Study: NCT01722318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03826134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PXT012253
Description: Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
Study: NCT04517422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
Study: NCT03687450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE yoga-based program
Description: The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
Study: NCT03016793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin
Description: purabone (puerarin) is a bone graft used for surgical repair of bony defects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β- tricalcium phosphate
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β- tricalcium phosphate alone
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
Study: NCT04410887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC+SOX+OLAPARIB
Description: SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
Study: NCT03651232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: once weekly group yoga class for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support group
Description: once weekly group support class for 12 weeks
Study: NCT04291105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VV1
Description: VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VV1
Description: VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VV1
Description: VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
Study: NCT03023111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sbv
Description: Standard treatment for CL, parenteral drug used during 20 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine plus placebo
Description: Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine plus GM-CSF
Description: Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
Study: NCT04199767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Description: Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Description: Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
Study: NCT04390672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRAFLEX Cruz
Description: Percutaneous Coronary Intervention for multivessel disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY
Description: Percutaneous Coronary Intervention for multivessel disease
Study: NCT06582407

Intervention type: OTHER
Intervention: Mathematical Prediction of unforseen patient reorientation
Description: The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery

Intervention type: OTHER
Intervention: Mathematical Prediction of unforseen patient reorientation
Description: The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
Study: NCT02710994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0209
Description: Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0209
Description: Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losec
Description: Losec 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losec
Description: Losec 40 mg
Study: NCT00811746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozerem (Ramelteon)
Description: 8 mg taken orally 30 minutes before a split-night PSG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lunesta (Eszopiclone)
Description: 3 mg taken orally 30 minutes before the start of a split-night PSG

Intervention type: OTHER
Group type: OTHER
Intervention: Historical Controls
Description: Chart review matched for demographics and comorbidities of the study drug groups.
Study: NCT01791634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proximal chevron osteotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal open wedge osteotomy with LPS system
Study: NCT01143623

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01805193

Intervention type: OTHER
Intervention: Computed tomography myocardial perfusion imaging

Intervention type: OTHER
Intervention: Oxygen 15 labelled water positron emission tomography
Study: NCT02600182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure
Description: Bilevel positive airway pressure twice per day during the hospital stay.
Study: NCT01157741

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: C-C
Description: Mx as H-C plus positioning follow up in the community clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-SF
Description: As C-C but with additional supplementary food (SF) (C-SF)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: As C-C with additional psychosocial stimulation (PS) (C-PS)
Description: Giving psychosocial stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: As C-C but with both SF & PS (C-SF+PS)
Description: Giving both SF \& PS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H-C
Description: Follow-up at Hospital
Study: NCT03990363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Verinurad
Description: Matching Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Allopurinol
Description: Matching tablet
Study: NCT02076867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Short-Term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care As Usual (MCAU)
Description: This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
Study: NCT01535131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palatoplasty
Description: procedure to close cleft palate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: palatoplasty
Description: procedure to close cleft palate
Study: NCT04177914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)
Description: Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal Shunt
Description: The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
Study: NCT03612518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text and Voice Messages
Description: Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Phone Call
Description: Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
Study: NCT02857660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body Electromyostimulation (exercise)
Description: 1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
Study: NCT02290366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal prostate brachytherapy with Cesium-131
Study: NCT02664779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arrhythmia diagnosis with the 10 steps method
Study: NCT03565302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Subjects are treated with daily inhalation of formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Subjects are treated with daily inhalation of terbutaline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are treated with placebo
Study: NCT01533181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linsitinib
Description: 150 mg given orally (PO) twice a day (BID)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: 1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
Study: NCT03317678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioKefir
Description: BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fermented milk
Description: A non-fermented milk drink.
Study: NCT03704571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens.
Study: NCT03052283

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire Patient Reported Outcome Measure (PROM)
Description: non-interventional

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire Patient Reported Outcome Measure (PROM)
Description: non-interventional
Study: NCT02950714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIN_NOW
Description: The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LIN_WAIT
Description: Usual care for three months prior to access to the LIN